Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Shareholding Reduction Plan for Shareholders with Over 5% Shares
Filed with SSE · · 4 pages · Chinese
Release
Earlier from Sinotherapeutics
- Announcement on Provision for Asset Impairment for 2025
- Summary Announcement on 2025 Restricted Stock Incentive Plan (Revised Draft)
- Announcement on Voluntary Disclosure of Clinical Trial Applications for Eisaiconazole Sulfate for Injection Approved by China NMPA
- Announcement on Appointment of Senior Management Members
- Announcement on Postponement of Investment Projects Financed by Raised Funds
Later from Sinotherapeutics
- Announcement on Voluntary Disclosure of the Proposed Selection of Products in the National Continuation Drug Procurement
- Announcement on Preliminary Earnings Estimate for 2025
- Announcement on Voluntary Disclosure of Obtaining US FDA Approval Number for the Company’s Vitamin K1 Tablets
- Announcement on Approval by Shanghai Municipal State-owned Assets Supervision and Administration Commission for Abstract of 2025 Restricted Stock Incentive Plan (Revised Draft)
- Announcement on Voluntary Disclosure of Clinical Trial Applications for Collaborative Product Enzalutamide Tablets Approved by China NMPA
Follow Sinotherapeutics into a list and get an email when it puts out news.
Follow Sinotherapeutics